Figure 1.1: Pathophysiology of RA…….2
Figure 1.2: Pathophysiology of Gout……...5
Figure 2.1: Immunosuppressive agents targeting T cell/antigen-presenting cell interaction and early T cell activation…….22
Figure 2.2: Transverse Section of Human Skin…….42
Figure 3.1: Typical HPLC overlay plot of TAC (25-125 µg/ml) (A) For analytical method and (B) For bioanalytical method…….74
Figure 3.2: Calibration plot of TAC for analytical method (A) at 0 Hr and (B) after 24 Hr using HPLC analytical method……76
Figure 3.3: Calibration plot of TAC for bioanalyical method (A) at 0 Hr and (B) after 24 Hr using HPLC analytical method……..76
Figure 3.4: Typical LC-MS plot of TAC (2-30 ng/ml)……..79
Figure 3.5: Calibration plot of TAC (A) at 0 Hr and (B) after 24 Hr using LCMS analytical method……80
Figure 3.6: Overly plot of FBX using HPLC (0.2-1.0 µg/ml) (A) for analytical method (B) for bioanalytical method……..83
Figure 3.7: Calibration plot for FBX using HPLC (A) Analytical method (B) Bioanalytical method……84
Figure 3.8: UV absorption spectra of FBX in (A) ACN:MOH (9:1) (B) Phosphate buffer pH 7.4……...87
Figure 3.9: Calibration curves of FBX in (A) ACN:MOH, (B) ACN:MOH after 24……...88
Figure 3.10: Absorption spectra of FBX (A) without blank cubosomal dispersion (B) in presence of cubosomal dispersion + Lactose to demonstrate specificity of analytical methods……..92
Figure 4.1: FT-IR spectrum (A) Reported FTIR spectra of TAC (B) Obtained FTIR spectra of TAC……99
Figure 4.2: DSC thermogram of TAC…….100
Figure 4.3: Solubility study of TAC in various solvent……...101
Figure 4.4: UV spectrum of FBX in methanol……102
Figure 4.5: FT-IR spectrum of FBX (A) Reported FTIR spectra of FTIR(12) (B) Obtained spectra of FTIR……103
Figure 4.6: DSC thermogram of FBX……..104

Figure 4.7: Solubility study of FBX in various solvent……...……105
Figure 4.8: (A) FTIR Spectra of TAC (B) FTIR spectra of mixture of TAC, Glyceryl Monooleate, Polyvinyl Alcohol, Lactose…….106
Figure 4.9: (A) FTIR spectra of FBX (B) FTIR spectra of FBX, Glyceryl Monooleate, Polyvinyl Alcohol, Lactose……..107
Figure 4.10: (A) DSC thermogram of TAC (B) DSC thermogram of mixture of TAC, Polyvinyl Alcohol, Lactose……..108
Figure 4.11: (A) DSC thermogram of FBX (B) DSC thermogram of FBX, Polyvinyl Alcohol, Lactose…….109
Figure 5.1: Bottom up approach for preparation of Tacrolimus loaded cubosomes……...115
Figure 5.2: Solubility study of Tacrolimus……..121
Figure 5.3: Ishikawa diagram showing probable variables that may influence the CQA……...129
Figure 5.4: Pareto and normal plots for (A): % Entrapment efficiency, (B) Vesicle size, (C) PDI…….136
Figure 5.5: Residuals plots for % entrapment efficiency…….145
Figure 5.6: Residuals plots for vesicle size……..146
Figure 5.7: Residuals plots for Polydispersity index (PDI)…….146
Figure 5.8: Contour and surface response plot of % entrapment efficiency……147
Figure 5.9: Contour and surface response plot of vesicle size…….148
Figure 5.10: Contour and surface response plot of polydispersity index (PDI)……..148
Figure 5.11: Overlay plot for the optimization of Tacrolimus loaded cubosomes using full quadratic model……149
Figure 5.12: Desirability contour plot for optimization of Tacrolimus loaded cubosomes using full quadratic model…….150
Figure 5.13: TEM images of Tacrolimus loaded cubosomes……..152
Figure 5.14: Zeta potential of the optimized Tacrolimus loaded cubosomes……..153
Figure 5.15: Vesicle size of the optimized Tacrolimus loaded cubosomes…….154
Figure 5.16: SAXS analysis of cubosomes of TAC……155
Figure 5.17: Residual estimation of ethanol in cubosomes of TAC……156
Figure 5.18: In-vitro drug release profile of TAC……...158
Figure 6.1: Bottom up approach for preparation of FBX loaded cubosomes……..164

Figure 6.2: Solubility study of FBX……171
Figure 6.3: Ishikawa diagram showing probable variables that may influence the CQA……..178
Figure 6.4: Pareto and normal plots for (A): % Entrapment efficiency, (B) PDI and (C) Vesicle size……...…185
Figure 6.5: Residuals plots for % entrapment efficiency…….194
Figure 6.6: Residuals plots for vesicle size……..195
Figure 6.7: Residuals plots for Polydispersity index (PDI)…….195
Figure 6.8: Contour and surface response plot of % entrapment efficiency……196
Figure 6.9: Contour and surface response plot of vesicle size…….196
Figure 6.10: Contour and surface response plot of polydispersity index (PDI)……..197
Figure 6.11: Overlay plot for the optimization of FBX loaded cubosomes using full quadratic model……198
Figure 6.12: Desirability contour plot for optimization of FBX loaded cubosomes using full quadratic model……199
Figure 6.13: TEM images of FBX loaded cubosomes…….201
Figure 6.14: Zeta potential of the optimized FBX loaded cubosomes……202
Figure 6.15: Vesicle size of the optimized FBX loaded cubosomes……...203
Figure 6.16: Scaterring pattern of optimized cubosomes of FBX……...204
Figure 6.17: Residual estimation of ethanol in final optimized batch of cubosomes of FBX…205
Figure 6.18: In-vitro drug release profile of FBX……207
Figure 7.1: Process for preparing micromould to prepare (A) TAC MN patch (B) FBX MN patch. In figure, 1 indicate dermastamp, 2 indicate dermastamp hold in primary (casting) mould and 3 indicate secondary micromould…….218
Figure 7.2: Ishikawa diagram showing probable variables that may influence the CQA……...220
Figure 7.3: Residual plots for AFF of cubosomes of TAC loaded MN Patch…….227
Figure 7.4: (A) Contour and (B) response surface plots for AFF of cubosomes of TAC loaded MN Patch…….228
Figure 7.5: Residual plots for in-vitro dissolution time of cubosomes of TAC loaded MN Patch…….232
Figure 7.6: (A) Contour and (B) response surface plots for in-vitro dissolution time of cubosomes of TAC loaded MN Patch…….233

Figure 7.7: Desirability plot for the optimization of cubosomes of TAC loaded MN Patch…...234
Figure 7.8: Overly plot for the optimization of cubosomes of TAC loaded MN Patch…..……235
Figure 7.9: Residual plots for AFF of cubosomes of FBX loaded MN Patch…….……241
Figure 7.10: (A) Contour and (B) response surface plots for AFF of cubosomes of FBX loaded MN Patch…….242
Figure 7.11: Residual plots for in-vitro dissolution time of cubosomes of FBX loaded MN Patch…….246
Figure 7.12: (A) Contour and (B) response surface plots for in-vitro dissolution time of cubosomes of FBX loaded MN Patch……..247
Figure 7.13: Desirability plot for the optimization of cubosomes of FBX loaded MN Patch….248
Figure 7.14: Overly plot for the optimization of cubosomes of FBX loaded MN Patch…….249
Figure 7.15: Load vs Time curve for MN patch loaded with cubosomes of TAC……..251
Figure 7.16: Load vs Time curve for MN patch loaded with cubosomes of FBX……..251
Figure 7.17: In-vitro dissolution study of MN patch containing TAC loaded cubosomes……..252
Figure 7.18: In-vitro dissolution study of MN patch containing FBX loaded cubosomes……..252
Figure 7.19: SEM of MN patch loaded with cubosomes of TAC (A) Top view (B) Side view……..253
Figure 7.20: SEM of MN patch loaded with cubosomes of TAC (A) Top view (B) Side view……..253
Figure 7.21: Skin penetrability of (A) Cubosomes of TAC loaded MN Patch and (B) Cubosomes of FBX loaded MN Patch……254
Figure 7.22: Pore closure kinetics for MN patch loaded with cubosomes of TAC…….255
Figure 7.23: Pore closure kinetics for MN patch loaded with cubosomes of FBX…….256
Figure 7.24: TEM of cubosomes after dissolving MN patch in water (A) For FBX (B) TAC...258
Figure 7.25: In-vitro drug release from developed MN patch formulation of TAC……260
Figure 7.26: In-vitro drug release from developed MN patch formulation of FBX……260
Figure 8.1: TAC drug distribution profile after 24 hours of permeation study……...273
Figure 8.2: FBX drug distribution profile after 24 hours of permeation study……276
Figure 8.3: Fluorescence microscopic images of rat skin sections after 12h of treatment with A) FITC suspension, B) cubosomes loaded with FITC, C) MN patch of FITC, D) MN patch loaded with FITC cubosomes……..277

Figure 8.4: % viability of fibroblast 3T3 cells after treatment with cubosomes of Tacrolimus..278
Figure 8.5: % viability of fibroblast 3T3 cells after treatment with cubosomes of Febuxostat...279
Figure 8.6: % viability of macrophage RAW 264.7 cells after treatment with cubosomes of Tacrolimus……...280
Figure 8.7: Histopathology study of developed formulation……...282
Figure 9.1: Plasma TAC concentration vs Time profile of various dosage forms in Sprague Dawley rats……..293
Figure 9.2: Plasma FBX concentration vs Time profile of various dosage forms in Sprague Dawley rats……..296
Figure 9.3: Paw volume determination for RA……298
Figure 9.4: Measurements of weight gain/loss during the pharmacodynamic study of TAC….299
Figure 9.5: Calibration plot for RF factor to find out RF factor in rat serum……..300
Figure 9.6: Measurement of Rheumatoid factor in rat serum……..301
Figure 9.7: X-ray of rat's paw to study the effectiveness of developed formulation of TAC…301
Figure 9.8: Measurement of serum uric acid level in rat serum……..…302
Figure 9.9: X-ray of rat's paw to study the effectiveness of developed formulation of FBX...303